Takeda Pharmaceutical Company Limited and Bio-Techne Corporation: A Detailed Gross Profit Analysis

Pharma vs. Biotech: A Decade of Profit Growth

__timestampBio-Techne CorporationTakeda Pharmaceutical Company Limited
Wednesday, January 1, 20142514110001256834000000
Thursday, January 1, 20153072770001271973000000
Friday, January 1, 20163366590001173296000000
Sunday, January 1, 20173745410001274610000000
Monday, January 1, 20184321430001437534000000
Tuesday, January 1, 20194734910002201424000000
Wednesday, January 1, 20204831940002203504000000
Friday, January 1, 20216328500002462160000000
Saturday, January 1, 20227564960002783406000000
Sunday, January 1, 20237698150002832257000000
Monday, January 1, 20247697250002832257000000
Loading chart...

Data in motion

A Comparative Analysis of Gross Profit Trends in the Pharmaceutical and Biotech Sectors

In the ever-evolving landscape of the pharmaceutical and biotech industries, understanding financial performance is crucial. This analysis delves into the gross profit trends of two industry giants: Takeda Pharmaceutical Company Limited and Bio-Techne Corporation, from 2014 to 2024.

Takeda, a leader in the pharmaceutical sector, has shown a remarkable growth trajectory. From 2014 to 2023, its gross profit surged by approximately 125%, reaching a peak of over 2.8 trillion in 2023. This growth underscores Takeda's strategic expansions and successful product launches.

Conversely, Bio-Techne, a prominent player in the biotech field, experienced a steady increase in gross profit, growing by over 200% during the same period. By 2023, Bio-Techne's gross profit approached 770 million, reflecting its innovative advancements and market penetration.

These trends highlight the dynamic nature of these sectors, with both companies showcasing resilience and adaptability in a competitive market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025